Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Hypersensitivity Reaction

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 52 articles:
HTML format

Single Articles

    May 2021
  1. REICH K, Teixeira HD, de Bruin-Weller M, Bieber T, et al
    Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 20. pii: S0140-6736(21)00589.
    PubMed     Abstract available

  2. GUTTMAN-YASSKY E, Teixeira HD, Simpson EL, Papp KA, et al
    Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Lancet. 2021 May 20. pii: S0140-6736(21)00588.
    PubMed     Abstract available

  3. THYSSEN JP, Thomsen SF
    Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
    Lancet. 2021 May 20. pii: S0140-6736(21)00717.

    January 2021
  4. SIMPSON EL, Bieber T, Thyssen JP, Valdez H, et al
    Abrocitinib for atopic dermatitis - Authors' reply.
    Lancet. 2021;397:196.

  5. UPPAL SK, Chat VS, Kearns DG, Wu JJ, et al
    Abrocitinib for atopic dermatitis.
    Lancet. 2021;397:195-196.

    September 2020
  6. SUNYER J, Anto JM
    Asthma exacerbations, air pollution, and allergens.
    Lancet. 2020;396:753.

  7. BURNEY P, Amaral AFS
    Asthma exacerbations, air pollution, and allergens - Authors' reply.
    Lancet. 2020;396:753-754.

  8. VON MUTIUS E, Smits HH
    Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention.
    Lancet. 2020 Sep 7. pii: S0140-6736(20)31861.
    PubMed     Abstract available

    August 2020
  9. LANGAN SM, Irvine AD, Weidinger S
    Atopic dermatitis.
    Lancet. 2020;396:345-360.
    PubMed     Abstract available

    July 2020
  10. SIMPSON EL, Sinclair R, Forman S, Wollenberg A, et al
    Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2020;396:255-266.
    PubMed     Abstract available

  11. WEIDINGER S, Schreiber S
    Abrocitinib for atopic dermatitis: a step forward.
    Lancet. 2020;396:215-217.

  12. LAM RPK, Wong KW, Wan CK
    Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
    Lancet. 2020 Jul 13. pii: S0140-6736(20)31560.

    February 2020
  13. PERRETT KP, Peters RL
    Emollients for prevention of atopic dermatitis in infancy.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)33174.

  14. SKJERVEN HO, Rehbinder EM, Vettukattil R, LeBlanc M, et al
    Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32983.
    PubMed     Abstract available

  15. CHALMERS JR, Haines RH, Bradshaw LE, Montgomery AA, et al
    Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32984.
    PubMed     Abstract available

    Perception of severity of adverse events in oral immunotherapy.
    Lancet. 2020;395:415.

  17. PETERS MC, Wenzel SE
    Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
    Lancet. 2020;395:371-383.
    PubMed     Abstract available

    December 2019
  18. BURNEY P, Amaral AFS
    Air pollution and chronic airway disease: is the evidence always clear?
    Lancet. 2019;394:2198-2200.

    November 2019
  19. BACHERT C, Han JK, Desrosiers M, Hellings PW, et al
    Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Lancet. 2019;394:1638-1650.
    PubMed     Abstract available

    October 2019
  20. THANGARAJU P, Venkatesan S
    A double blow for a patient with leprosy: a reversal reaction and an adverse drug reaction.
    Lancet. 2019;394:1450.

  21. VAN REE R
    Sustained unresponsiveness in peanut oral immunotherapy.
    Lancet. 2019;394:1392-1393.

    September 2019
  22. FITZGERALD JM, Sadatsafavi M
    Triple therapy in a single inhaler: a new option for uncontrolled asthma.
    Lancet. 2019 Sep 30. pii: S0140-6736(19)32216.

  23. VIRCHOW JC, Kuna P, Paggiaro P, Papi A, et al
    Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Lancet. 2019 Sep 30. pii: S0140-6736(19)32215.
    PubMed     Abstract available

  24. CHINTHRAJAH RS, Purington N, Andorf S, Long A, et al
    Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Lancet. 2019 Sep 12. pii: S0140-6736(19)31793.
    PubMed     Abstract available

    August 2019
  25. GAUTHIER M, Wenzel SE
    As-needed beta agonist-inhaled corticosteroid in mild asthma.
    Lancet. 2019 Aug 23. pii: S0140-6736(19)31994.

  26. HARDY J, Baggott C, Fingleton J, Reddel HK, et al
    Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
    Lancet. 2019 Aug 23. pii: S0140-6736(19)31948.
    PubMed     Abstract available

    June 2019
    Prevalence and burden of asthma in China: time to act.
    Lancet. 2019 Jun 20. pii: S0140-6736(19)31349.

  28. HUANG K, Yang T, Xu J, Yang L, et al
    Prevalence, risk factors, and management of asthma in China: a national cross-sectional study.
    Lancet. 2019 Jun 20. pii: S0140-6736(19)31147.
    PubMed     Abstract available

  29. ROBERTS G, Angier E
    Peanut oral immunotherapy: balancing benefits and risks for individuals.
    Lancet. 2019;393:2180-2181.

    April 2019
  30. CHU DK, Wood RA, French S, Fiocchi A, et al
    Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
    Lancet. 2019 Apr 25. pii: S0140-6736(19)30420.
    PubMed     Abstract available

    March 2019
    Health and wellbeing in adolescence and early adulthood.
    Lancet. 2019;393:847.

    December 2018
  32. BLUMENTHAL KG, Peter JG, Trubiano JA, Phillips EJ, et al
    Antibiotic allergy.
    Lancet. 2018 Dec 14. pii: S0140-6736(18)32218.
    PubMed     Abstract available

    September 2018
  33. VALENZUELA PL, Santos-Lozano A, Morales JS, Drobnic F, et al
    Free to breathe hard in the Tour de France.
    Lancet. 2018;392:1114-1115.

    April 2018
  34. RIEDL MA, Relan A, Harper JR, Cicardi M, et al
    C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.
    Lancet. 2018;391:1356.

  35. MULLER YD, Harr T, Dayer E, Seebach JD, et al
    C1 esterase inhibitor concentrates and attenuated androgens.
    Lancet. 2018;391:1355-1356.

    February 2018
    Asthma in US children.
    Lancet. 2018;391:632.

    January 2018
  37. MOSLER G, Euba T
    Taking control through drama.
    Lancet. 2018;391:303-304.

  38. WATTS G
    Ian Pavord: engaging with the eosinophil.
    Lancet. 2018;391:301.

  39. CROOKS MG, Faruqi S, Morice AH
    How does azithromycin improve asthma exacerbations?
    Lancet. 2018;391:28.

    How does azithromycin improve asthma exacerbations? - Author's reply.
    Lancet. 2018;391:28-29.

    December 2017
  41. PAPI A, Brightling C, Pedersen SE, Reddel HK, et al
    Lancet. 2017 Dec 19. pii: S0140-6736(17)33311.
    PubMed     Abstract available

    October 2017
  42. AERTS O, Herman A, Bruze M, Goossens A, et al
    FreeStyle Libre: contact irritation versus contact allergy.
    Lancet. 2017;390:1644.

    September 2017
  43. KLEINERT S, Horton R
    After asthma: airways diseases need a new name and a revolution.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32205.

  44. PAVORD ID, Beasley R, Agusti A, Anderson GP, et al
    After asthma: redefining airways diseases.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)30879.

    Transformational thinking about asthma.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32126.

  46. WOODCOCK A, Vestbo J, Bakerly ND, New J, et al
    Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32397.
    PubMed     Abstract available

  47. GIBSON P
    Effectiveness trials in asthma: time to SaLSA?
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32398.

    July 2017
  48. BRUSSELLE G, Pavord I
    Azithromycin in uncontrolled asthma.
    Lancet. 2017 Jul 4. pii: S0140-6736(17)31547.

    March 2017
  49. FITZGERALD JM, Emery P
    Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology?
    Lancet. 2017;389:1082-1084.

    December 2016
  50. WENZEL SE, Jayawardena S, Graham NM, Pirozzi G, et al
    Severe asthma and asthma-chronic obstructive pulmonary disease syndrome - Authors' reply.
    Lancet. 2016;388:2742.

  51. XIA Y, Cao C, Li W, Shen H, et al
    Severe asthma and asthma-chronic obstructive pulmonary disease syndrome.
    Lancet. 2016;388:2741-2742.

    October 2016
  52. ZINK A, Bohner A, Schuch A, Biedermann T, et al
    Systemic mastocytosis with generalised skin involvement.
    Lancet. 2016 Oct 13. pii: S0140-6736(16)31710.

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.